The global transdermal drug delivery system market size was estimated to be US$ 5.5 billion in 2021 and is expected to grow at a CAGR of 6.3% between 2023 to 2032.
Transdermal drug delivery is a method of drug administration wherein the drugs are delivered through the skin to achieve systemic dispersion across the entire body. Transdermal drug delivery systems work as a type of controlled release mechanism in which medications are given through the skin at a specified and regulated pace. Transdermal drug delivery technologies are used to treat a variety of diseases, including cardiovascular illnesses and neurological problems.
Some of the drugs supplied using transdermal skin patches are nicotine (for smoking cessation), nitro-glycerine (for angina), scopolamine (for motion sickness), and lidocaine (for shingles pain), among others. These products have several advantages, including a longer therapeutic impact, fewer adverse effects, increased bioavailability, improved patient compliance, and simple drug therapy discontinuation. The appendageal, transcellular, and intercellular channels are the three primary ways of drug entry using the transdermal drug delivery system.
The growing number of geriatric patients across the world and the increase in chronic ailments such as musculoskeletal diseases and aging disorders among the elderly are driving up the market for skin-based drug patches. Furthermore, transdermal drug delivery systems provide various advantages such as improved safety, efficiency, and decreased inter-patient variation of dosages. All of these factors are significantly driving the growth of the global transdermal drug delivery systems market.
The increase in the demand for drug self-administration for patients with long-term ailments is among the primary growth drivers for global transdermal drug delivery systems products. It is predicted that the transdermal drug delivery systems market would see new demands as the mobile/online health segment develops. As patients start to realize the available choices the benefits of such systems might aid market expansion for transdermal drug delivery systems.
Increased preference of patients for pain-free drug administration is also predicted to enable a greater acceptance of adhesive skin patches which will help to fuel the growth of the transdermal drug delivery systems market. this feature will also offer revenue-generating opportunities for leading industry participants during the forecasted period.
Advances in conventional pharmaceutical delivery systems with a rising emphasis on skin-based drug delivery are projected to fuel demand and contribute to the overall growth of this market. Other factors, such as advancements in the customized health management sector with the introduction of advanced materials and enhanced features will help patients and help the transdermal drug delivery category to emerge as one of the top revenue producers in the future.
Despite all of the foregoing development opportunities, the high cost of transdermal patches as compared to other conventional treatment options, as well as poor penetration in emerging regions will limit the transdermal drug delivery system's market growth.
During the projection period, the pain management category is expected to have the greatest share of the market in transdermal drug delivery system products. One of the primary factors driving the segment's growth in the global market is the increased use of opioid medicine patches in pain treatment, particularly among cancer patients.
Because of the increased need for transdermal drug delivery systems to treat patients suffering from various ailments, the hospital sector is likely to provide the most revenue to the global transdermal drug delivery market during the forecast period of our report.
North America dominated the transdermal drug delivery system devices market until now, and this dominance is expected to remain at the top spot throughout the forecast period. The increased frequency of conditions such as chronic pain, cancer, and cardiovascular disease, as well as research efforts done by market participants to offer new products in the region, are major factors linked to the leadership position.
Because of increased chronic disease prevalence and expanding disease awareness in both developed and emerging markets like China and India, Asia Pacific is predicted to be the highest revenue-generating region in the global market. Because of established healthcare infrastructure facilities in nations such as the United Kingdom and Germany, Europe is also expected to see high growth in the global transdermal drug delivery systems market during the forecast years.
Increased healthcare expenditure, rising medical consciousness, and growing investments by different regional players in the creation of innovative patches are some of the drivers driving the continent's expansion of the transdermal drug delivery systems market.
Other parts of the world, such as Latin America, the Middle East, and Africa, are likely to have modest growth in the total transdermal drug delivery systems market in the forecast period, due to the lack of well-established market participants in these regions.
The global transdermal drug delivery systems market is extremely competitive, with many major competitors present in all regions. Many of these firms are likely to be responsible for a sizable portion of the overall market in the future. Prominent market players may get into collaboration arrangements with smaller competitors to boost their market position and profit margin.
Leading market firms may also invest in the mobile and online health category, allowing it to emerge as the fastest-expanding market in the next years. In the approaching years, R&D projects might be a crucial revenue-generating business strategy for big players in the transdermal drug delivery system market.
Some of the major players present in the transdermal drug delivery system market are 3M, Mylan, AdhexPharma, DuPont, Endo International, Lubrizol Corporation, Novartis AG, Purdue Pharma L.P., and others.
By Type
By Application
By End User
By Geography
The global transdermal drug delivery system market is geared to grow at a CAGR of 6.3% from 2023 to 2032.
Increase in the demand for drug self-administration by patients with long-term ailments is among the primary growth drivers for global transdermal drug delivery systems market.
The high cost of transdermal patches when compared to other conventional treatment options and poor penetration in under developed regions will limit the market growth for Transdermal Drug Delivery System.
Transdermal drug delivery system market size was estimated to be US$ 5.5 billion in 2021.
3M, Mylan, AdhexPharma, DuPont, Endo International, Lubrizol Corporation, Novartis AG, Purdue Pharma L.P., and others are among the global leaders in Transdermal Drug Delivery System Market.
The pain management category is expected to have the greatest share of the market in transdermal drug delivery system products. One of the primary factors driving the segment's growth in the global market is the increased use of opioid medicine patches in pain treatment, particularly among cancer patients.
North America dominated the transdermal drug delivery system devices market until now, and this dominance is expected to remain at the top spot throughout the forecast period.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved